Olivia's Feed
Sep 22, 2014

Allergan revives talks to acquire Salix: source

NEW YORK (Reuters) – Allergan Inc (AGN.N: Quote, Profile, Research, Stock Buzz) has revived discussions to buy Salix Pharmaceuticals Ltd (SLXP.O: Quote, Profile, Research, Stock Buzz), a person familiar with the matter said on Monday, asking not to be identified because the talks are confidential.

The exact status of the discussions between the two drugmakers could not be immediately established. Spokesmen for Allergan and Salix declined to comment.

Sep 18, 2014

Exclusive: Vitamin Shoppe gets investor push to sell itself – sources

NEW YORK (Reuters) – A handful of large shareholders are calling on nutritional supplement retailer Vitamin Shoppe Inc (VSI.N: Quote, Profile, Research, Stock Buzz) to consider a sale to private equity or larger rival GNC Holdings Inc (GNC.N: Quote, Profile, Research, Stock Buzz), according to people familiar with the matter.

At least one activist fund has accumulated a position and has held conversations with members of the Vitamin Shoppe board about a potential sale, the people said, asking not to be named because the matter is not public. It is considering whether to go public with its push, the people added.

Sep 16, 2014

Exclusive: Top investors push Salix to abandon Cosmo deal – sources

NEW YORK (Reuters) – A number of top 20 investors at Salix Pharmaceuticals Ltd (SLXP.O: Quote, Profile, Research, Stock Buzz) are threatening to vote down the company’s proposed deal to buy a unit of Cosmo Pharmaceuticals (COPN.S: Quote, Profile, Research, Stock Buzz) and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

Raleigh, North Carolina-based Salix, which makes drugs for gastrointestinal disorders, said in July it would merge with Cosmo’s Irish subsidiary, a deal that would allow Salix to move its tax domicile abroad in a practice known as inversion.

Sep 15, 2014

SABMiller soars on ignited hopes of takeover by AB InBev

NEW YORK/LONDON (Reuters) – SABMiller (SAB.L: Quote, Profile, Research, Stock Buzz) shares surged to an all-time high on Monday on hopes a long-rumored takeover bid by the world’s largest brewer Anheuser-Busch InBev (ABI.BR: Quote, Profile, Research, Stock Buzz) may be getting closer.

SABMiller shares first rose 5 percent on news its bid for Heineken (HEIN.AS: Quote, Profile, Research, Stock Buzz), seen by some as a tactic to fend off AB InBev, had been rebuffed. SABMiller then leapt after a report that AB InBev was talking to bankers about funding a takeover.

Sep 12, 2014

Exclusive: Jimmy John’s Gourmet Sandwiches chain weighs stake sale – sourcesĀ 

NEW YORK (Reuters) – The Jimmy John’s Gourmet Sandwiches chain is considering selling a major stake in the company and has hired boutique investment bank North Point Advisors to advise on a potential deal, according to people familiar with the matter.

Jimmy John’s, founded in 1983 by 19-year old Jimmy John Liautaud in a converted garage, is in the early stage of preparing a sale process, the people said. It remains unclear how big a stake the Champaign, Illinois-based company will eventually offer potential investors.

Sep 12, 2014

Jimmy John’s Gourmet Sandwiches chain weighs stake sale -sources

NEW YORK, Sept 12 (Reuters) – The Jimmy John’s Gourmet
Sandwiches chain is considering selling a major stake in the
company and has hired boutique investment bank North Point
Advisors to advise on a potential deal, according to people
familiar with the matter.

Jimmy John’s, founded in 1983 by 19-year old Jimmy John
Liautaud in a converted garage, is in the early stage of
preparing a sale process, the people said. It remains unclear
how big a stake the Champaign, Illinois-based company will
eventually offer potential investors.

Sep 11, 2014

Exclusive: Akorn eyes $2 billion UCB unit in potential tax inversion – sources

NEW YORK (Reuters) – U.S. specialty drugmaker Akorn Inc (AKRX.O: Quote, Profile, Research, Stock Buzz) is exploring a bid for Belgian drugmaker UCB SA’s (UCB.BR: Quote, Profile, Research, Stock Buzz) U.S. subsidiary, a deal that would allow the company to move its tax domicile overseas in a practice known as inversion, according to people familiar with the matter.

UCB is looking to sell its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc, in a deal that could fetch as much as $2 billion, Reuters reported last month.

Sep 11, 2014

Allergan investors owning 35 pct to demand special meeting -sources

NEW YORK, Sept 11 (Reuters) – Billionaire William Ackman has
signed up Allergan investors who combined own at least
35 percent of the Botox maker to call a special shareholder
meeting, according to people familiar with the matter, giving
the hedge fund manager a victory in his fight to acquire
Allergan.

Ackman, whose Pershing Square Capital Management is
Allergan’s largest shareholder with a 9.7 percent stake, has
teamed up with Canada’s Valeant Pharmaceuticals International
Inc to pursue a hostile takeover bid for Allergan.

Sep 5, 2014

Dave & Busters to file for IPO as early as next week -sources

NEW YORK, Sept 5 (Reuters) – Dave & Buster’s Inc is
preparing to file for an initial public offering as soon as next
week, according to people familiar with the matter, adding to a
spate of restaurant chains that have gone public this year to
tap strong investor demand.

The Dallas-based restaurant and arcade chain, owned by
private equity firm Oak Hill Capital Partners, is working with
banks including Jefferies LLC and Piper Jaffray on the offering,
the people said.

Sep 5, 2014

Dollar General new bid may not sway Family Dollar-sources

NEW YORK, Sept 5 (Reuters) – Dollar General Corp’s
sweetened $9.1 billion proposal to buy Family Dollar Stores Inc
may fall short of allaying its smaller rival’s fears
U.S. antitrust regulators will block the deal, according to two
sources familiar with the matter.

Family Dollar already has a deal to sell itself to rival
discount retailer Dollar Tree Inc for $8.5 billion.
Dollar General, the largest U.S. dollar store, first appeared as
an interloper last month with a $8.95 billion competing bid, or
$78.50 per share, but Family Dollar rejected the offer saying it
could run afoul of competition laws.